Ticlopidine aspirin stroke study: Outcome by vascular distribution of the qualifying event

Area of Science:

• Neurology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Stroke remains a leading cause of death and disability worldwide.
• Identifying effective antiplatelet therapies is crucial for secondary stroke prevention.
• The Ticlopidine Aspirin Stroke Study (TASS) investigated the efficacy of ticlopidine versus aspirin.

Purpose of the Study:

• To compare the effectiveness of ticlopidine and aspirin in preventing recurrent stroke and death.
• To analyze outcomes based on the vascular distribution of the initial ischemic event (carotid vs. vertebrobasilar).

Main Methods:

• Analysis of patient data from the Ticlopidine Aspirin Stroke Study (TASS).
• Stratification of outcomes by vascular territory: carotid circulation and vertebrobasilar circulation.
• Comparison of 1-year risk reduction for death or nonfatal stroke and fatal or nonfatal stroke.

Main Results:

• Ticlopidine demonstrated a 49.7% risk reduction for fatal or nonfatal stroke in the carotid circulation compared to aspirin.
• In the vertebrobasilar circulation, ticlopidine showed a 46% risk reduction, though not statistically significant (NS).
• Overall stroke risk reduction was 24.6% for carotid events and 28.0% for vertebrobasilar events with ticlopidine.

Conclusions:

• Ticlopidine is a more effective agent than aspirin for secondary stroke prevention in patients with carotid artery disease.
• While ticlopidine use was associated with a higher incidence of overall adverse events, serious or life-threatening events were comparable to aspirin.
• The findings support ticlopidine as a valuable therapeutic option, particularly for carotid circulation ischemic events.